Gossamer Bio Inc (GOSS)
$0.806
Insights on Gossamer Bio Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 63.0%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 335.4%
Performance
- $0.79$0.86$0.81
2.46%
Downside
Day's Volatility :7.87%
Upside
5.55%
- $0.45$1.88$0.81
44.14%
Downside
52 Weeks Volatility :75.93%
Upside
56.91%
Returns
| Period | Gossamer Bio Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -5.71% | -0.7% | 0.0% |
6 Months | 36.67% | 6.6% | 0.0% |
1 Year | -16.3% | 3.7% | -1.5% |
3 Years | -90.2% | 14.0% | -21.8% |
Highlights
Market Capitalization | 185.2M |
Book Value | $0.28 |
Earnings Per Share (EPS) | -1.18 |
Wall Street Target Price | 5.72 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -37.17% |
Return On Equity TTM | -480.5% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -172.2M |
Diluted Eps TTM | -1.18 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.76 |
EPS Estimate Next Year | -0.7 |
EPS Estimate Current Quarter | -0.21 |
EPS Estimate Next Quarter | -0.19 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 609.68%
Technicals Summary
Sell
Neutral
Buy
Gossamer Bio Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Gossamer Bio Inc | -40.58% | 36.67% | -16.3% | -90.2% | -94.95% |
 Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
 Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
 Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
 Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Gossamer Bio Inc | NA | NA | NA | -0.76 | -4.8 | -0.37 | NA | 0.28 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Gossamer Bio Inc | Buy | $185.2M | -94.95% | NA | 0.0% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Institutional Holdings
NEA Management Company, LLC
7.02%FMR Inc
5.44%Artal Group S A
5.35%Vanguard Group Inc
5.16%EcoR1 Capital, LLC
4.08%Octagon Capital Advisors LP
3.63%
Corporate Announcements
Gossamer Bio Inc Earnings
Gossamer Bio Inc’s price-to-earnings ratio stands at None
Read More
Company Information
gossamer bio is a san diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. founded by the former receptos executive team, gossamer bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
Organization | Gossamer Bio Inc |
Employees | 135 |
CEO | Mr. Faheem Hasnain |
Industry | Pharmaceuticals: Major |
